Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs"
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Adverse reactions
- Sponsors AbbVie
- 09 May 2018 Planned number of patients changed from 600 to 305.
- 19 Feb 2018 Status changed from not yet recruiting to recruiting.
- 15 Nov 2017 New trial record